Dianthus Therapeutics (DNTH) Share-based Compensation (2017 - 2025)

Dianthus Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $5.8 million for Q3 2025.

• In Q3 2025, Share-based Compensation rose 50.89% year-over-year to $5.8 million; the TTM figure through Sep 2025 stood at $20.7 million (up 113.7% YoY), while the FY2024 annual figure was $41.5 million, up 425.32% from the prior year.
• Share-based Compensation for Q3 2025 stood at $5.8 million, up from $5.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $5.8 million in Q3 2025, with the low at $462000.0 in Q2 2023.
• The 5-year median for Share-based Compensation is $2.1 million (2021), against an average of $2.5 million.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation sank 82.6% in 2022, then jumped 571.21% in 2024.
• Dianthus Therapeutics' Share-based Compensation stood at $2.2 million in 2021, then tumbled by 76.5% to $513000.0 in 2022, then surged by 41.52% to $726000.0 in 2023, then jumped by 439.67% to $3.9 million in 2024, then soared by 47.88% to $5.8 million in 2025.
• Business Quant data shows DNTH's Share-based Compensation at $5.8 million in Q3 2025, $5.7 million in Q2 2025, and $5.3 million in Q1 2025.